Analyst Ratings For CymaBay Therapeutics Inc (NASDAQ:CBAY)
Today, Oppenheimer set its price target on CymaBay Therapeutics Inc (NASDAQ:CBAY) to $20.00 per share.
There are 9 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on CymaBay Therapeutics Inc (NASDAQ:CBAY) is Buy with a consensus target price of $21.8750 per share, a potential 103.49% upside.
Some recent analyst ratings include
- 8/9/2018-CymaBay Therapeutics Inc (NASDAQ:CBAY) had its Buy rating reiterated by Cantor Fitzgerald with a $16.00 price target
- 6/28/2018-CymaBay Therapeutics Inc (NASDAQ:CBAY) has coverage initiated with a Outperform rating and $20.00 price target
- 6/6/2018-CymaBay Therapeutics Inc (NASDAQ:CBAY) had its Buy rating reiterated by HC Wainwright with a $23.00 price target
- 3/16/2018-CymaBay Therapeutics Inc (NASDAQ:CBAY) had its Buy rating reiterated by SunTrust Banks with a $19.00 price target
Recent Insider Trading Activity For CymaBay Therapeutics Inc (NASDAQ:CBAY)
CymaBay Therapeutics Inc (NASDAQ:CBAY) has insider ownership of 4.50% and institutional ownership of 95.48%.
- On 8/29/2018 Daniel Menold, VP, sold 5,000 with an average share price of $13.00 per share and the total transaction amounting to $65,000.00.
- On 7/27/2018 Sujal Shah, CEO, bought 5,000 with an average share price of $10.90 per share and the total transaction amounting to $54,500.00.
- On 6/5/2018 Kurt Von Emster, Director, sold 920 with an average share price of $12.51 per share and the total transaction amounting to $11,509.20.
- On 5/11/2018 Sujal Shah, CEO, bought 5,000 with an average share price of $10.65 per share and the total transaction amounting to $53,250.00.
- On 3/22/2018 Carl Goldfischer, Director, sold 15,000 with an average share price of $13.03 per share and the total transaction amounting to $195,450.00.
- On 3/5/2018 Kurt Von Emster, Director, sold 13,353 with an average share price of $15.51 per share and the total transaction amounting to $207,105.03.
- On 2/14/2018 Kurt Von Emster, Director, sold 218,057 with an average share price of $15.89 per share and the total transaction amounting to $3,464,925.73.
About CymaBay Therapeutics Inc (NASDAQ:CBAY)
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops arhalofenate, which has completed five Phase II clinical trials for the treatment of patients with gout; and MBX-2982, an oral G-protein coupled receptor agonist that has completed one Phase II clinical trial for therapeutic indications. It has licensing agreement with Kowa Pharmaceuticals America, Inc. for the development and commercialization of arhalofenate in the United States; and Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders, as well as a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Recent Trading Activity for CymaBay Therapeutics Inc (NASDAQ:CBAY)
Shares of CymaBay Therapeutics Inc closed the previous trading session at 10.75 −0.56 4.95% with 10.65 shares trading hands.
